Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Ractigen Therapeutics announced completion of patient enrollment and initial dosing across all cohorts in its Phase II trial evaluating its next-generation RNA therapeutics. The update is an early clinical progress milestone, generally supportive but without reported efficacy/safety or readout timing. Overall, modestly positive near-term sentiment with limited likely market-wide impact.

Analysis

Ractigen Therapeutics announced completion of patient enrollment and initial dosing across all cohorts in its Phase II trial evaluating its next-generation RNA therapeutics. The update is an early clinical progress milestone, generally supportive but without reported efficacy/safety or readout timing. Overall, modestly positive near-term sentiment with limited likely market-wide impact.